Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.
Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, Lieberman JA. Jarskog LF, et al. Neuropsychopharmacology. 2013 Jun;38(7):1245-52. doi: 10.1038/npp.2013.23. Epub 2013 Jan 16. Neuropsychopharmacology. 2013. PMID: 23325325 Free PMC article. Clinical Trial.
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.
Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, Girgis RR, Sobeih T, Wall MM, Choo TH, Green MF, Yang YS, Lee J, Horga G, Krystal JH, Potter WZ, Javitt DC, Lieberman JA. Kantrowitz JT, et al. Neuropsychopharmacology. 2020 Oct;45(11):1842-1850. doi: 10.1038/s41386-020-0706-z. Epub 2020 May 13. Neuropsychopharmacology. 2020. PMID: 32403118 Free PMC article. Clinical Trial.
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
Sehatpour P, Javitt DC, De Baun HM, Carlson M, Beloborodova A, Margolin DH, Carlton MBL, Brice NL, Kantrowitz JT. Sehatpour P, et al. Neuropsychopharmacology. 2022 Feb;47(3):711-718. doi: 10.1038/s41386-021-01170-8. Epub 2021 Oct 20. Neuropsychopharmacology. 2022. PMID: 34667294 Free PMC article. Clinical Trial.
365 results